FDA Inspection 1304064 — Padagis US LLC

Padagis US LLC — FEI 2127022

The FDA completed an inspection of Padagis US LLC on April 8, 2026 in Minneapolis, MN. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 7 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
April 8, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Minneapolis, MN (United States)

Citations

IDCFRDescription
136121 CFR 211.100(a)Absence of Written Procedures
191821 CFR 211.166(a)(2)Stability sample storage conditions described
2271721 CFR 117.130(a)(1)Hazard analysis - Identification of hazard
2284721 CFR 111.70(e)Specifications - finished dietary supplement
308021 CFR 114.83Scheduled process establishment
360321 CFR 211.160(b)Scientifically sound laboratory controls
430221 CFR 211.56(b)Written sanitation procedures not followed